The following corrections should be considered.(i)In the text on page 3, replace the number of reference [26] by [25].(ii)In the text on page 3, replace the number of reference [27] by [26].(iii)In the text on page 3, replace the number of reference [28] by [27].(iv)In the text on page 3, replace the number of reference [29] by [28].(v)In the text on page 3, replace the number of reference [30] by [29].(vi)In the text on page 3, replace the number of reference [31] by [30].(vii)In the text on page 3, replace the number of reference [32] by [31].(viii)In the text on page 3, replace the number of reference [33] by [32].(ix)In the text on page 3, replace the number of reference [34] by [33].(x)In the text on page 3, replace the number of reference [35] by [34].(xi)In the text on page 3, replace the number of reference [36] by [35].(xii)In the text on page 3, replace the number of reference [37] by [36].(xiii)In the text on page 4, replace the number of reference [25] by [37].(xiv)In the legend of Figure 1, replace the number of reference [25] by [37].(xv)Please consider the following corrected reference list for paper.
Erratum to “Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities”
The following corrections should be considered.(i)In the text on page 3, replace the number of reference [26] by [25].(ii)In the text on page 3, replace the number of reference [27] by [26].(iii)In the text on page 3, replace the number of reference [28] by [27].(iv)In the text on page 3, replace the number of reference [29] by [28].(v)In the text on page 3, replace the number of reference [30] by [29].(vi)In the text on page 3, replace the number of reference [31] by [30].(vii)In the text on page 3, replace the number of reference [32] by [31].(viii)In the text on page 3, replace the number of reference [33] by [32].(ix)In the text on page 3, replace the number of reference [34] by [33].(x)In the text on page 3, replace the number of reference [35] by [34].(xi)In the text on page 3, replace the number of reference [36] by [35].(xii)In the text on page 3, replace the number of reference [37] by [36].(xiii)In the text on page 4, replace the number of reference [25] by [37].(xiv)In the legend of Figure 1, replace the number of reference [25] by [37].(xv)Please consider the following corrected reference list for paper.
References
C. M. Lawes, S. V. Hoorn, and A. Rodgers, “Global burden of blood-pressure-related disease, 2001,” The Lancet, vol. 371, no. 9623, pp. 1513–1518, 2008.
View at: Publisher Site | Google ScholarL. M. Brown, “Essential hypertension,” National Medical Association, vol. 21, no. 1, pp. 1–4, 1929.
View at: Google ScholarG. Londres, Ed., Hipertensão Arterial, vol. 235, Livraria Agir Editora, Rio de Janeiro, Brazil, 1945.
R. Tigerstedt and P. G. Bergman, “Niere und kerislauf,” Skandinavisches Archiv für Physiologie, vol. 8, pp. 223–271, 1898.
View at: Google ScholarF. N. White and A. Grollman, “Autoimmune factors associated with infarction of the kidney,” Nephron, vol. 204, pp. 93–102, 1964.
View at: Google ScholarB. Rodríguez-Iturbe, H. Pons, Y. Quiroz et al., “Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure,” Kidney International, vol. 59, no. 6, pp. 2222–2232, 2001.
View at: Publisher Site | Google ScholarA. Virdis and E. L. Schiffrin, “Vascular inflammation: a role in vascular disease in hypertension?” Current Opinion in Nephrology and Hypertension, vol. 12, no. 2, pp. 181–187, 2003.
View at: Publisher Site | Google ScholarC. de Ciuceis, F. Amiri, P. Brassard, D. H. Endemann, R. M. Touyz, and E. L. Schiffrin, “Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2106–2113, 2005.
View at: Publisher Site | Google ScholarP. Wenzel, M. Knorr, S. Kossmann et al., “Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction,” Circulation, vol. 124, no. 12, pp. 1370–1381, 2011.
View at: Google ScholarJ. Shao, M. Nangaku, T. Miyata et al., “Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury,” Hypertension, vol. 42, no. 1, pp. 31–38, 2003.
View at: Publisher Site | Google ScholarT. J. Guzik, N. E. Hoch, K. A. Brown et al., “Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction,” Journal of Experimental Medicine, vol. 204, no. 10, pp. 2449–2460, 2007.
View at: Publisher Site | Google ScholarC. Nataraj, M. I. Oliverio, R. B. Mannon et al., “Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway,” Journal of Clinical Investigation, vol. 104, no. 12, pp. 1693–1701, 1999.
View at: Google ScholarM. Jurewicz, D. H. McDermott, J. M. Sechler et al., “Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1093–1102, 2007.
View at: Publisher Site | Google ScholarN. E. Hoch, T. J. Guzik, W. Chen et al., “Regulation of T-cell function by endogenously produced angiotensin II,” American Journal of Physiology, vol. 296, no. 2, pp. R208–R216, 2009.
View at: Publisher Site | Google ScholarP. J. Marvar, S. R. Thabet, T. J. Guzik et al., “Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension,” Circulation Research, vol. 107, no. 2, pp. 263–270, 2010.
View at: Publisher Site | Google ScholarA. Fiebeler, F. Schmidt, D. N. Müller et al., “Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin II-induced cardiac injury,” Hypertension, vol. 37, no. 2, pp. 787–793, 2001.
View at: Google ScholarR. Rocha, A. E. Rudolph, G. E. Frierdich et al., “Aldosterone induces a vascular inflammatory phenotype in the rat heart,” American Journal of Physiology, vol. 283, no. 5, pp. H1802–H1810, 2002.
View at: Google ScholarM. F. Neves, F. Amiri, A. Virdis, Q. N. Diep, and E. L. Schiffrin, “Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy,” Canadian Journal of Physiology and Pharmacology, vol. 83, no. 11, pp. 999–1006, 2005.
View at: Publisher Site | Google ScholarA. Virdis, M. F. Neves, F. Amiri, E. Viel, R. M. Touyz, and E. L. Schiffrin, “Spironolactone improves angiotensin-induced vascular changes and oxidative stress,” Hypertension, vol. 40, no. 4, pp. 504–510, 2002.
View at: Publisher Site | Google ScholarI. Z. Jaffe and M. E. Mendelsohn, “Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells,” Circulation Research, vol. 96, no. 6, pp. 643–650, 2005.
View at: Publisher Site | Google ScholarA. J. Rickard and M. J. Young, “Corticosteroid receptors, macrophages and cardiovascular disease,” Journal of Molecular Endocrinology, vol. 42, no. 6, pp. 449–459, 2009.
View at: Publisher Site | Google ScholarE. Leibovitz, T. Ebrahimian, P. Paradis, and E. L. Schiffrin, “Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction,” Journal of Hypertension, vol. 27, no. 11, pp. 2192–2200, 2009.
View at: Publisher Site | Google ScholarX. L. Wang, D. L. Rainwater, J. F. VandeBerg, B. D. Mitchell, and M. C. Mahaney, “Genetic contributions to plasma total antioxidant activity,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 7, pp. 1190–1195, 2001.
View at: Google ScholarY. Taniyama and K. K. Griendling, “Reactive oxygen species in the vasculature: molecular and cellular mechanisms,” Hypertension, vol. 42, no. 6, pp. 1075–1081, 2003.
View at: Publisher Site | Google ScholarM. Sedeek, R. L. Hébert, C. R. Kennedy, K. D. Burns, and R. M. Touyz, “Molecular mechanisms of hypertension: role of Nox family NADPH oxidases,” Current Opinion in Nephrology and Hypertension, vol. 18, no. 2, pp. 122–127, 2009.
View at: Publisher Site | Google ScholarE. Y. Lee, M. S. Shim, M. J. Kim, S. Y. Hong, Y. G. Shin, and C. H. Chung, “Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes,” Experimental and Molecular Medicine, vol. 36, no. 1, pp. 65–70, 2004.
View at: Google ScholarN. J. Brown, “Aldosterone and vascular inflammation,” Hypertension, vol. 51, no. 2, pp. 161–167, 2008.
View at: Publisher Site | Google ScholarD. J. Kelly, A. J. Cox, R. M. Gow, Y. Zhang, B. E. Kemp, and R. E. Gilbert, “Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo,” Hypertension, vol. 44, no. 2, pp. 195–202, 2004.
View at: Publisher Site | Google ScholarC. A. Akdis and M. Akdis, “Mechanisms and treatment of allergic disease in the big picture of regulatory T cells,” Journal of Allergy and Clinical Immunology, vol. 123, no. 4, pp. 735–746, 2009.
View at: Publisher Site | Google ScholarB. M. Hall, M. E. Jelbart, K. E. Gurley, and S. E. Dorsch, “Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells,” Journal of Experimental Medicine, vol. 162, no. 5, pp. 1683–1694, 1985.
View at: Google ScholarB. R. Powell, N. R. M. Buist, and P. Stenzel, “An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy,” Journal of Pediatrics, vol. 100, no. 5, pp. 731–737, 1982.
View at: Google ScholarX. Valencia and P. E. Lipsky, “CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases,” Nature Clinical Practice Rheumatology, vol. 3, no. 11, pp. 619–626, 2007.
View at: Publisher Site | Google ScholarM. C. Rodriguez-Galan, J. H. Bream, A. Farr, and H. A. Young, “Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1/Th2 cytokine expression,” Journal of Immunology, vol. 174, no. 5, pp. 2796–2804, 2005.
View at: Google ScholarP. Pandiyan, L. Zheng, S. Ishihara, J. Reed, and M. J. Lenardo, “CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells,” Nature Immunology, vol. 8, no. 12, pp. 1353–1362, 2007.
View at: Publisher Site | Google ScholarY. Belkaid, “Regulatory T cells and infection: a dangerous necessity,” Nature Reviews Immunology, vol. 7, no. 11, pp. 875–888, 2007.
View at: Publisher Site | Google ScholarM. I. Garin, N. C. Chu, D. Golshayan, E. Cernuda-Morollón, R. Wait, and R. I. Lechler, “Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells,” Blood, vol. 109, no. 5, pp. 2058–2065, 2007.
View at: Publisher Site | Google ScholarT. Barhoumi, D. A. Kasal, M. W. Li et al., “T Regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury,” Hypertension, vol. 57, no. 3, pp. 469–476, 2011.
View at: Publisher Site | Google ScholarD. A. Kasal, T. Barhoumi, M. W. Li et al., “T regulatory lymphocytes prevent aldosterone-induced vascular injury,” Hypertension, vol. 59, no. 2, pp. 324–330, 2012.
View at: Publisher Site | Google ScholarN. M. Al-Daghri, O. S. Al-Attas, M. S. Alokail et al., “Gender-specific associations between insulin resistance, hypertension, and markers of inflammation among adult Saudis with and without diabetes mellitus type 2,” Advances in Medical Sciences, vol. 55, no. 2, pp. 179–185, 2010.
View at: Publisher Site | Google ScholarB. M. Y. Cheung, K. L. Ong, A. W. K. Tso et al., “C-reactive protein as a predictor of hypertension in the Hong Kong cardiovascular risk factor prevalence study (CRISPS) cohort,” Journal of Human Hypertension, vol. 25, no. 2, pp. 108–116, 2011.
View at: Publisher Site | Google Scholar